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Gene domain-specific DNA methylation
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Abstract
Background: ADNP syndrome is a rare Mendelian disorder characterized by global developmental delay,
intellectual disability, and autism. It is caused by truncating mutations in ADNP, which is involved in chromatin
regulation. We hypothesized that the disruption of chromatin regulation might result in specific DNA methylation
patterns that could be used in the molecular diagnosis of ADNP syndrome.
Results: We identified two distinct and partially opposing genomic DNA methylation episignatures in the
peripheral blood samples from 22 patients with ADNP syndrome. The “epi-ADNP-1” episignature included ~ 6000
mostly hypomethylated CpGs, and the “epi-ADNP-2” episignature included ~ 1000 predominantly hypermethylated
CpGs. The two signatures correlated with the locations of the ADNP mutations. Epi-ADNP-1 mutations occupy the
N- and C-terminus, and epi-ADNP-2 mutations are centered on the nuclear localization signal. The episignatures
were enriched for genes involved in neuronal system development and function. A classifier trained on these
profiles yielded full sensitivity and specificity in detecting patients with either of the two episignatures. Applying
this model to seven patients with uncertain clinical diagnosis enabled reclassification of genetic variants of
uncertain significance and assigned new diagnosis when the primary clinical suspicion was not correct. When
applied to a large cohort of unresolved patients with developmental delay (N = 1150), the model predicted three
additional previously undiagnosed patients to have ADNP syndrome. DNA sequencing of these subjects, wherever
available, identified pathogenic mutations within the gene domains predicted by the model.
Conclusions: We describe the first Mendelian condition with two distinct episignatures caused by mutations in a
single gene. These highly sensitive and specific DNA methylation episignatures enable diagnosis, screening, and
genetic variant classifications in ADNP syndrome.
Keywords: Epigenetics, Episignature, DNA methylation, ADNP, Helsmoortel-Van der Aa syndrome, Autism,
Intellectual disability, Unresolved clinical cases, Disease screening
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Background
ADNP syndrome (Helsmoortel-van der Aa syndrome;
OMIM# 615873) is caused by dominant negative truncating variants in ADNP [1]. This disorder is among the most
common causes of syndromic autism spectrum disorder
(ASD) and intellectual disability (ID) and frequently tops
the list of genes mutated in large-scale neurodevelopmental
disorder sequencing cohorts [2, 3]. As a group, neurodevelopmental disorders are difficult to diagnose clinically, and
ADNP syndrome exemplifies the challenges faced in this
area. The major clinical features of ADNP syndrome include global developmental delay, ID, and ASD. These are
often accompanied by additional comorbid features with
variable expressivity (i.e., hypotonia, gastrointestinal, behavioral and sleep problems) [4]. In order to advance our ability to diagnose and eventually treat ADNP syndrome and
similar conditions, additional biomarkers will be useful for
variant classification, cohort screening, and functional analysis. Whole genome methylation analysis offers significant
promise to realize these goals.
The ADNP gene encodes activity-dependent neuroprotective protein (ADNP), which is ubiquitously expressed
and involved in chromatin remodeling and gene expression. ADNP is important for brain development and may
be linked to cognitive ability [5, 6]. The sequence motifs
of the ADNP protein include nine zinc-fingers, a nuclear
localization signal, a DNA-binding homeobox motif, and
an HP1-binding motif. In most cell types, ADNP is localized in the nucleus and recruited to histone H3K9me3
marked heterochromatin by HP1 [7]. ADNP directly interacts with members of the BRG1/Brm-associated factor
(BAF) complex including ARID1A, SMARCA4, and
SMARCC2 [1, 8]. The BAF complex (SWI/SNF in yeast
and Brahma in Drosophila) is a 15-subunit protein complex that modifies the placement of nucleosomes along
the length of DNA molecules by hydrolyzing ATP. The
BAF family of chromatin remodelers regulates gene expression, thereby influencing cell differentiation, neural
development, and learning and memory [9].
The identification of human neurodevelopmental disorders caused by genes involved in chromatin regulation is
increasing and now includes more than 28 genes encoding
chromatin regulators [10]. Eight of the 15 subunits of the
BAF complex have been implicated in neurodevelopmental disorders [10]. Pathogenic variants in these genes cause
Coffin-Siris syndrome and Nicolaides-Baraitser syndrome;
both have considerable phenotypic overlap with ADNP
syndrome including global developmental delay, hypotonia, intellectual disability, gastrointestinal complications,
and behavioral problems. Recently, defects in BAF complex members and several other chromatin remodeling
genes have been shown to have syndrome-specific
genome-wide DNA methylation signatures, the so-called
episignatures [11–17]. These studies have shown that
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changing histone marks leads to alternative methylation of
genomic DNA, and this phenomenon can be leveraged to
diagnose disease.
Here, we demonstrate that ADNP syndrome co-occurs
with unique genomic DNA methylation changes in the
peripheral blood. Uniquely, defects in ADNP produce
two episignatures with partially contrasting methylation
patterns which correlate with the location of the mutations. We describe in details the overlap and dissimilarities of the two episignatures and demonstrate the
enrichment of the harboring genes in neuronal system
pathways. We show that these changes are specific to
ADNP syndrome and do not occur in other neurodevelopmental conditions. By computational modeling of the
two episignatures, we show that they can be successfully
applied to resolve ambiguous clinical/molecular cases,
provide new diagnosis when the initial clinical assumption is not correct, and identify novel ADNP cases
through screening of a large cohort of undiagnosed subjects presenting with intellectual disability.

Results
Clinical description of patients with ADNP syndrome

This study included 22 subjects with confirmed clinical
and molecular diagnoses of ADNP syndrome (Table 1).
Nine of the individuals provided detailed clinical phenotype information, which was consistent with that reported in other studies [1, 4]. Briefly, intellectual
disability, developmental delay, hypotonia, and ASD
were the only consistent features. Comorbidities were diverse and sporadic. Early developmental delays were
mild, and the average age at diagnosis was 5 years (range
1 year 3 months to 11 years 8 months). Facial dysmorphism is subtle in ADNP syndrome, and no consistent patterns were appreciated in our cohort. All 22 patients
with definitive ADNP syndrome were diagnosed by gene
panels or whole exome sequencing. All had premature
termination variants, and were determined to be de novo
by Sanger sequencing of the (self-reporting) parents or
trio exome analysis. The most common ADNP nonsense
variant described (p.Tyr719*) occurred in six patients
resulting from c.2157C>A or c.2157C>G. Phenotypic
features observed in patients with this mutation were
representative of the entire cohort. This study includes
the first patient reported with a truncating N-terminal
mutation in the first coding exon (exon 3; c.103dupA;
p.Ile35Asnfs*5; phenotype described in Additional file 1:
Figure S1). This novel mutation broadens the mutational
spectrum of ADNP syndrome.
Mutations in ADNP cause two distinct episignatures with
partially opposite DNA methylation profiles

Genome-wide DNA methylation analysis was performed
on peripheral blood DNA from the 22 subjects with

Bend et al. Clinical Epigenetics

(2019) 11:64

Page 3 of 17

Table 1 Twenty-two subjects with a confirmed clinical/molecular diagnosis of ADNP syndrome
ID

Age at blood draw

Sex

ADNP variant

Variant effect

Subtype

ADNP_03a

11

M

c.103dupA (p.Ile35Asnfs*5)

Frame-shift

ADNP-1

Training

ADNP_17

12

F

c.190dupA (p.Thr64Asnfs*35)

Frame-shift

ADNP-1

Training

Dataset

ADNP_16

4

M

c.539_542delTTAG (p.Val180Glyfs*17)

Frame-shift

ADNP-1

Testing

ADNP_25

5

M

c.819delC (p.Lys274Asnfs*31)

Frame-shift

ADNP-1

Training

ADNP_29

3

M

c.859_862dup (p.Gly288Aspfs*27)

Frame-shift

ADNP-1

Training

ADNP_23

10

M

c.1046_1047delTG (p.Leu349Argfs*49)

Frame-shift

ADNP-1

Testing

ADNP_08

2

M

c.1102C>T (p.Gln368*)

Nonsense

ADNP-1

Training

ADNP_05a

2

M

c.1106_1108delTACinsCTGT (p.Leu369Serfs*30)

Frame-shift

ADNP-1

Training

ADNP_12

4

F

c.1222_1223delAA (p.Lys408Valfs*31)

Frame-shift

ADNP-1

Training

ADNP_20

9

F

c.1287dupT (p.Ala430Cysfs*10)

Frame-shift

ADNP-1

Training

ADNP_15

12

F

c.2156_2157insA (p.Tyr719*)

Nonsense

ADNP-2

Training

ADNP_07

5

F

c.2157C>A (p.Tyr719*)

Nonsense

ADNP-2

Testing

ADNP_10

5

F

c.2157C>A (p.Tyr719*)

Nonsense

ADNP-2

Training

ADNP_14

5

M

c.2157C>A (p.Tyr719*)

Nonsense

ADNP-2

Training

ADNP_04

12

F

c.2157C>G (p.Tyr719*)

Nonsense

ADNP-2

Training

ADNP_11

4

F

c.2157C>G (p.Tyr719*)

Nonsense

ADNP-2

Testing

ADNP_21

4

M

c.2188C>T (p.Arg730*)

Nonsense

ADNP-2

Testing

ADNP_13

3

M

c.2268dup (p.Lys757Glnfs*4)

Frame-shift

ADNP-2

Training

ADNP_24

10

M

c.2287delT (p.Ser763Profs*9)

Frame-shift

ADNP-2

Training

ADNP_22

3

M

c.2287dupT (p.Ser763Phefs*3)

Frame-shift

ADNP-2

Training

ADNP_02a

8

M

c.2340T>G (p.Tyr780*)

Nonsense

ADNP-2

Training

ADNP_09

12

M

c.2419_2423delAAAAG (p.Lys807Glufs*6)

Frame-shift

ADNP-1

Testing

a

The DNA methylation profiles of these three subjects were examined from blood samples collected years apart to evaluate the changes in the ADNP episignature
over time (Additional file 1: Figure S1). Individuals are listed in ascending order according to the cDNA nomenclature. Mean ± standard deviation of all patients’
age 6.8 ± 3.8 (36% females), matched controls 7.9 ± 5.7 (37% females); epi-ADNP-1 subtype 7.2 ± 4.2 (25% females), matched controls 7.3 ± 4.2 (28% females); epiADNP-2 subtype age 6.3 ± 3.6 (32% females), matched controls 5.6 ± 3.6 (35% females); ADNP transcript NM_015339.2; Photographs of some of these subjects are
provided in Additional file 1: Figure S1

confirmed clinical and molecular diagnoses of ADNP syndrome using Illumina Infinium EPIC arrays. Following
normalization and quality controls, 770,508 CpG sites
(probes) were retained for analysis. A comparison was performed between these patients and 88 age- and
sex-matched controls. The analysis identified 1320 probes
with a minimum of 10% methylation difference between
the two groups and a multiple-testing corrected p value <
0.01 (limma multivariable regression modeling), adjusted
for blood cell type compositions. Hierarchical clustering
and multiple dimensional scaling demonstrated that the
selected probes separated the patients from controls.
However, the ADNP cases clustered in two distinct groups
with a greater distance from each other than from controls (Fig. 1). We determined that the groups did not correlate with differences in age, sex, or technical batch
structure of the methylation experiment. The epigenetic
clustering was shown to correlate with the positions of the
mutations within ADNP. Samples with 5′ ADNP mutations (upstream of cDNA nucleotide c.1300) clustered
with one sample with a 3′ deletion (c.2419_2423del). For

this group, the episignature was defined as the ADNP-1
episignature and the sub-cohort defined as the
epi-ADNP-1 cohort (n = 11). The remaining samples, with
mutations occurring between c.2000 and c.2340, generated the second cluster (the ADNP-2 episignature,
epi-ADNP-2 cohort, n = 11, Fig. 1).
We split the cohort based on the two episignatures and
conducted a separate analysis for each according to the
same criteria described above. Comparison of the
epi-ADNP-1 cohort (n = 11) with 44 matched controls
identified 5987 differentially methylated probes—most
were hypomethylated in the patients (Additional file 2:
Table S1). Analysis of the 11 patients from the
epi-ADNP-2 cohort matched with 44 controls identified
1374 CpG sites (Additional file 2: Table S2). Each of these
two probe-sets alone was capable of distinguishing between the subjects with epi-ADNP-1, epi-ADNP-2, and
controls as demonstrated using clustering analyses (Fig. 2).
The ADNP-2 episignature had a smaller effect size and
harbored a probe count equal to a quarter of that in the
ADNP-1 episignature. Almost half the probes contributing
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Fig. 1 Correlation between the genetic coordinates of the ADNP mutations and two ADNP episignatures. Comparison of patients with ADNP
syndrome and controls identified 1320 differentially methylated CpG sites. a Illustration of the top two dimensions of the multiple dimensional
scaling of the patients (purple) and controls (green) using these probes reveals that while patients are separated from controls, they are clustered
in two groups (indicated with dashed circles) with greater distances from each other than from controls. b A hierarchical clustering generates a
similar pattern in which 11 ADNP cases generate one distinct cluster mainly representing hypomethylation events (epi-ADNP-1, blue-dashed
rectangle), and the other 11 subjects generate a cluster different from both controls and the first cluster (epi-ADNP-2, red-dashed rectangle),
showing a slightly hypermethylated pattern relative to controls. Notably, methylation changes in epi-ADNP-1 are more prominant than those in
epi-ADNP-2. The top pane in the heatmap indicates the phenotype. Green, controls; purple, epi-ADNP syndrome. The heatmap color scale from
blue to red represents the range of the methylation levels (beta values) between 0 and 1. c Evaluation of the genetic coordinates of the
mutations reveals that, with the exception of one, all epi-ADNP-1 subjects have a mutation upstream c.1300, and all epi-ADNP-2 cases have
mutations occurring between c.2000 and c.2340. The only exception is found for one epi-ADNP-1 patient having a mutation after c.2400. d A
schematic representation of the mutations across the ADNP protein is presented in the bottom of the figure. Blue and red indicate the protein
coordinates of the mutations related with ADNP-1 and ADNP-2 episignatures, respectively. Domains outside these two had no mutations in
our cohort

to the ADNP-2 episignature (n = 541) were found to be
differentially methylated in the ADNP-1 episignature.
However, the methylation differences of this shared component were mostly in opposite directions. Within the
ADNP-1 episignature, CpGs were mostly hypomethylated
whereas they were predominantly hypermethylated in the
ADNP-2 episignature (Fig. 2). In all the analyses above, a
subject with a mutation in the most 3′ end of the
epi-ADNP-2 cohort region (c.2340T>G; p.Tyr780*)
showed the mildest ADNP-2 episignature methylation
pattern, intermediate between samples from the

epi-ADNP-2 cohort and controls (Fig. 2). DNA methylation analysis of whole blood specimens collected 6–9 years
apart from three subjects with ADNP syndrome confirmed that the observed patterns do not change over time
(Additional file 1: Figure S2).
The two ADNP episignatures have limited overlap and
differ in methylation properties

We compared the methylation profiles of the two ADNP
episignatures by aligning the coordinates of the differentially methylated regions (DMRs) and assessing the
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Fig. 2 Two distinct and partially contrasting episignatures in ADNP syndrome. Separate analyses for the two identified clusters in ADNP-1 and
ADNP-2 episignatures identified a larger number of probes for each group, indicating that the primary analysis had concealed the full spectrum
of the methylation profiles of ADNP syndrome. Blue, red, and green (in points and panes) represent epi-ADNP-1, epi-ADNP-2, and control
subjects, respectively. Using multiple dimensional scaling and hierarchical clustering analyses, it is shown that epi-ADNP-1 is associated with a
mainly hypomethylated episignature (a, b). Probes associated with ADNP-1 episignature also separate epi-ADNP-2 subjects from controls, but
with a milder opposite pattern of DNA methylation change (a, b). Similar observations are noted for epi-ADNP-2 specific probes (c, d), as well as
the intersection of the two episignatures (e, f). The shared component (e, f) generates the most contrasting pattern between the two subtypes.
Among the epi-ADNP-2 samples, a subject with a mutation in the most extreme end of the ADNP-2 region (c.2340T>G) shows the mildest
changes of all (black arrows)

direction of methylation changes. Using the DMRcate algorithm [18], we prioritized a total of 308 DMRs for the
ADNP-1 episignature and 57 DMRs for the ADNP-2
episignature based on the following criteria: three or
more probes less than 1 kb apart, > 10% average regional
methylation change, and a false discovery rate (FDR) of
< 0.01, adjusted for blood cell type compositions (Additional file 2: Tables S3–S4). The vast majority of the
DMRs identified in the ADNP-1 episignature involved
hypomethylation events (n = 293, 95%), whereas hypermethylation predominated in the ADNP-2 episignature
(n = 30, 53%).
For every region identified, we examined the methylation
status in the other ADNP episignature (Additional file 2:

Tables S3-S4). From the 308 DMRs in the ADNP-1 episignature, 174 (56%) were not differentially methylated in
the ADNP-2 episignature. The most prominent DMRs in
this category include 38% hypomethylation at
chr11:133445802–133446415 (intergenic), 31% hypomethylation in chr11:13508769–13509032 (10 kb upstream PTH),
and 29% hypomethylation in chr13:20392406–20392981 (8
kb upstream ZMYM5) (Fig. 3 and Additional file 1: Figure
S3–S13). Among the ADNP-1 episignature DMRs, 108
(35%) showed an opposite direction, and 26 (9%) showed
the same direction of methylation change in the
epi-ADNP-2 cohort (Additional file 1: Figures S14–S15).
Most of these changes had a smaller effect size in the
epi-ADNP-2 cohort than in epi-ADNP-1 and, in many
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Fig. 3 Regions differentially methylated in epi-ADNP-1 and epi-ADNP-2. Approximately 56% of the differentially methylated regions (DMRs) in
epi-ADNP-1 and 26% of DMRs in epi-ADNP-2 are specific to the subtypes in which they are identified. Although the remaining DMRs are shared
across the two subtypes, in the majority of instances they show contrasting methylation patterns. The small number of regions showing the
same direction of change in epi-ADNP-1 and epi-ADNP-2 (< 10% of DMRs) tend to represent small levels of methylation change and do not
generate fully overlapping patterns in epi-ADNP-1 and epi-ADNP-2. a At the most differentially methylated region (intergenic) in epi-ADNP-1 (blue),
no methylation change is observed in the epi-ANDP-2 cases (red) relative to controls (green). b An intronic region in RBM26 is hemimethylated in
epi-ADNP-2 cases while showing a hypomethylated pattern in controls and ADNP-1. c A region in the gene body of HSPA12B represents an example
of a contrasting DNA methylation change in epi-ADNP-1 and epi-ADNP-2, being hypo- and hypermethylated in each, respectively. d A region in the
terminal end of the PACSIN1 gene is among the very few DMRs showing a considerable methylation change in the same direction (hypomethylation)
in both episignatures. In this region, however, the two subtypes are still distinguishable from each other by epi-ADNP-2 showing an intermediate
pattern between epi-ADNP-1 and controls. X-axis, genomic coordinate; Y-axis, DNA methylation levels between 0 and 1; circles, DNA methylation level
for every individual at one CpG site, methylation patterns in all DMRs are provided in Additional file 1: Figures S2–S14

cases, did not meet the strict cut offs applied in DMR mapping. These statistics were slightly different for the ADNP-2
episignature DMRs: 15 (26%) were found to be unaffected,
33 (58%) showed a contrasting pattern, and 9 (15%) had a
change in the same direction in epi-ADNP-1.
Almost all the DMR coordinates shared between the
two episignatures (~ 91%) represented changes in opposite
directions (i.e., hypomethylation vs. hypermethylation),
and the number of changes in the same direction was low
and restricted to DMRs with low effect sizes. Within this
latter category (~ 9%), despite a shared direction of
change, the extent of methylation difference was not similar 60% of the time, with the epi-ADNP-2 cohort most
often showing an intermediate methylation level between
the epi-ADNP-1 cohort and controls. The main DMRs in
this category include a change in chr16:29703339–
29703480 (3 probes), mapping to the gene bodies of
BOLA2 and QPRT (27% and 17% hypomethylation in
epi-ADNP-1 and epi-ADNP-2), and another in
chr6:34498714–34500043 (8 probes), encompassing a

hypomethylation event in exon 9 of PACSIN1 in
epi-ADNP-1 (17%) and epi-ADNP-2 (11%, Fig. 3). These
analyses indicated that the episignatures of epi-ADNP-1
and epi-ADNP-2 cohorts are two distinct and partially
contrasting entities with a very small shared component.
Genes involved in neuronal function are enriched in the
ADNP-1 and ADNP-2 episignatures

To assess the functional significance of genes represented in the two methylation profiles, we performed
gene-set, pathway, and protein interaction analyses on
all of the genes annotating to a differentially methylated
CpG identified here. Gene-set analysis identified six gene
ontology (GO) terms enriched in the ADNP-1 episignature (FDR < 0.01) including cell communications, flavonoid metabolism, and synaptic signaling (Additional file 2:
Table S5). No GO terms identified in the ADNP-2 episignature met the conservative FDR threshold of 0.01,
likely due to the small number of genes involved. The
most significant terms identified in this analysis,
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We conducted interaction analysis of the proteins produced by genes with differentially methylated promoters
using the EpiMod algorithm [34]. This analysis identified a
total of nine protein–protein interaction network hotspots
containing a minimum of 10 interacting partners and an
FDR < 0.01 for the ADNP-1 episignature (Additional file 2:
Table S10). The most active of these hotspots centered on
the SFN protein. SFN had the greatest modularity index for
the ADNP-1 episignature (6.98 compared to < 2.5 in all
others) and was the only hotspot to meet the specified criteria in the ADNP-2 episignature. However, the predicted
direction of change in gene expression for the interacting
members was opposite between ADNP-1 and ADNP-2 episignatures (Additional file 2: Table S11). SFN is located at
the center of an interaction network of proteins including
HYAL2, NBEA, NBR1, AURKAIP1, RALGPS2, and
SLC1A2, some of which have known involvement in brain
function and neurological disease.

however, included extracellular matrix organization and
central nervous system development. Additional file 2:
Tables S5–S6 show all GO terms with a p value < 0.01 in
ADNP-1 and ADNP-2 episignatures. Analysis of the
combination of CpGs from the two profiles detected the
same GO terms identified for ADNP-1 as the most significant biological processes (FDR < 0.01, Additional file
2: Table S7).
Pathway analysis of the ADNP-1 episignature identified 14 pathways (FDR < 0.01), the most prominent of
which were neuronal system followed by extracellular
matrix organization (Additional file 2: Table S8). No
pathway was enriched in the ADNP-2 episignature,
again, likely due to the small number of genes. Analysis
of the combination of ADNP-1 and ADNP-2 episignatures retained neuronal system and extracellular matrix
organization as the most significant pathways but additionally prioritized neuronal transmission across chemical synapses (Additional file 2: Table S9, Fig. 4 and
Additional file 1: Figure S16). The genes involved in the
neuronal system, were two-fold more likely to occur in
the ADNP episignatures compared with the total number of genes tested in the EPIC array (p value = 7.79E−
09, FDR = 8.82E− 06).

Development of a classification model for ADNP
syndrome

The presence of two distinct methylation profiles in patients with ADNP syndrome suggested that DNA methylation data could be used to develop a classification model

Neuronal System

Collagen formation
Extracellular matrix organization

NCAM1 interactions
O−linked glycosylation

O−glycosylation of TSR domain−containing proteins

Extracellular matrix organization

Transmission across Chemical Synapses

NCAM1 interactions
NCAM signaling for neurite out−growth
Cardiac conduction

Defective B3GALTL

Muscle contraction

O−linked glycosylation
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NCAM signaling for neurite out−growth
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Neuronal System
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0.002
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Netrin−1 signaling

Cardiac conduction
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Fig. 4 Pathways enriched in the genes in ADNP signatures. The color intensity from blue to red represents the degree of significance (p value).
The size of each circle indicates the number of genes from each pathway that are present in the ADNP episignatures. The thickness of the
connecting lines corresponds to the level of interactions and relatedness between the pathways. Neuronal system is the most significant
pathway in this analysis and with the greatest number of genes (X-axis of the box on top right). Extracellular matrix organization and transmission
across chemical synapses are the next most significant pathways. An interactive map of the genes from ADNP episignatures involved in these
pathways is shown in Additional file 1: Figure S15
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for detection of ADNP cases and differentiation between
ADNP-1 and ADNP-2 episignatures. All 22 affected patients were randomly divided into two cohorts of training
(75% subset, n = 16) and testing (25% subset, n = 6). The
two episignatures were equally represented in both training and testing subsets (Table 1). A sample of 64 controls
was matched to the training subset for feature selection
and model training. We limited the analysis to probes
shared by both EPIC and 450k platforms (n = 399,092).
Probes were filtered to those with a minimum of 10%
methylation difference from controls (ADNP-1 episignature, n = 3876; ADNP-2 episignature, n = 1358). The
probes differentially methylated in both ADNP-1 and
ADNP-2 episignatures were expected to maximally distinguish the two groups; therefore, only shared probes were
retained for feature selection (n = 461). From these, probes
that provided the greatest separation between all three
groups (ADNP-1, ADNP-2, and controls) were selected

using the pairwise measurement of the area under the receiver operating characteristic curve (AUC; n = 163, Additional file 2: Table S12). This final probe list was used to
train a multi-class support vector machine (SVM) with
linear kernel on the training cohort. The model was set to
generate three scores ranging from zero to one for any
given subject, representing the confidence in predicting
whether the subject has a DNA methylation profile resembling that in the epi-ADNP-1, epi-ADNP-2, or controls.
The class obtaining the greatest score determined the episignature classification. Ten-fold cross-validation during
the training process resulted in an average accuracy of
100% (model details in Additional file 2: Table S12).
A series of tests were performed to challenge the reliability of the model. First, the entire training cohort was
classified by the model. The correct classifications were
assigned to all subjects predicted to have an ADNP-1 or
ADNP-2 episignature, with scores significantly different

epi-ADNP-1

epi-ADNP-2

Healthy

Other syndromes

Suspected

Undiagnosed

1.0
0.8
0.6
0.4
0.2
0.0

1.0
0.8
0.6
0.4
0.2
0.0

1.0
0.8
0.6
0.4
0.2
0.0
None

None

Fig. 5 Scores generated for different subjects by the ADNP classification model. A 3-class SVM classifier generates three scores (0–1) for every
subject as the probability of having a DNA methylation profile similar to what is observed in epi-ADNP-1, epi-ADNP-2, or none of these. The Yaxis represents scores 0–1, generated for each of the three classes on the X-axis. Every point represents a single sample. Hollow points indicate
the training samples and filled points indicate the testing samples. By default, the SVM classifier defines a cutoff of 0.5 for assigning the class;
however, the vast majority of the tested individuals received a score < 0.2 or > 0.8. Therefore, to improve visualization, the points are jittered. The
first two top panels show trials performed for known cases of epi-ADNP-1 and epi-ADNP-2, all of which were classified into the correct
categories. The middle two panels illustrate trials performed on 2315 healthy individuals (left) and 780 patients with neurodevelopmental
syndromes other than ADNP (right), all of which are scored low for both episignatures, but have received very high scores for the non-ADNP
category. This latter group includes subjects diagnosed with imprinting defects (Angelman, Prader-Willi, Beckwith-Wiedemann, and Silver-Russell
syndromes), non-syndromic autism spectrum disorders, BAFopathies (Coffin-Siris, Nicolaides-Baraitser, and Chr6q25 microdeletion syndromes),
RASopathies, autosomal dominant cerebellar ataxia, deafness, and narcolepsy, ATRX, Coffin-Lowry, Cornelia de Lange, CHARGE, CHOPS, ClaesJensen, Coffin-Lowry, Down, Dup7, Floating-Harbor, Fragile X, Genitopatellar, Juberg-Marsidi, Kabuki, Rett, Saethre-Chotzen, Sotos, Weaver, and
Williams syndromes. The last two panels show trials performed for suspected and unresolved cases. Among the suspected cases (n = 7), who
based on clinical or molecular assessments are ADNP candidates, one is classified as epi-ADNP-1 and one other as epi-ADNP-2. Unresolved
subjects include 1150 undiagnosed patients with neurodevelopmental presentations, among which three have been classified as epi-ADNP-1
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from the other two classes (Fig. 5). Next, we confirmed
that the model is not sensitive to the experimental batch
structure by classifying novel control samples processed
on the same batch as patients. All were appropriately classified as controls. Additionally, we evaluated the extent to
which the model is sensitive to variations in blood cell
type composition. The model was used to classify methylation array data derived from diverse sample types from
six healthy individuals, downloaded from the gene expression omnibus (GEO, GSE35069) [19]. The samples included whole blood, peripheral blood mononuclear cells,
and granulocytes, as well as seven isolated cell populations
(CD4+ T, CD8+ T, CD56+ NK, CD19+ B, CD14+ monocytes, neutrophils, and eosinophils) from six individuals.
All of these samples were classified as controls with scores
similar to those generated for the whole blood samples.
The average inter-cell type variability in the scores was <
5% (Additional file 2: Table S13).
To validate the model, it was applied to the methylation data from the testing cohort, composed of three individuals known to have an ADNP-1 episignature and
three with an ADNP-2 episignature. These data were
completely unfamiliar to the model and had not been
used for feature selection or training. All samples were
assigned the expected class with scores similar to those
of the training dataset, confirming that the model is robust in the classification of all three classes (Fig. 5). To
measure the specificity of the classifier, we tested whole
blood methylation data from 2315 healthy subjects of
various racial backgrounds (aged 0–94) obtained from
GEO (GSE42861, GSE85210, GSE87571, GSE87648, and
GSE99863) [20–23]. All subjects were classified as controls (Fig. 5). Next, we tested whether the model could
differentiate individuals with ADNP syndrome from
those with other neurodevelopmental disorders. DNA
methylation profiles from 780 subjects with a confirmed
diagnosis of a syndromic condition, including trinucleotide repeat expansion abnormalities, imprinting defect
disorders, RASopathies, BAFopathies, Mendelian disorders of the epigenetic machinery, Down syndrome, as
well as 140 patients with non-syndromic autism
spectrum disorders (details in Fig. 5), were supplied to
the model for classification. All samples were classified
as controls, further confirming the specificity of this
classifier.
Classification of subjects with an uncertain diagnosis of
ADNP syndrome

We assessed the utility of this model for classifying subjects with a clinical suspicion for ADNP syndrome
(Table 2, Fig. 5). First, we studied a sample from an individual with a clinical diagnosis of ADNP syndrome, but
for whom genetic information was not available. This
sample was classified as having the ADNP-2 episignature
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(ADNP-1 0.04, ADNP-2 0.90, and control 0.06), predicting that a pathogenic variant must exist between c.2000
and c.2340 in ADNP. Subsequent sequencing identified a
nonsense variant in the expected region (c.2156dupA;
p.Tyr719*; Fig. 5).
Missense variants in ADNP have been associated with
disease in the literature [24–26]. However, this evidence
may be insufficient to establish missense variation as a
mechanism for disease [1, 4]. With this uncertainty, clinical labs frequently report rare missense variants in ADNP
as uncertain significance (VUS), affecting a significant portion of patients with non-specific developmental delay
(DD), ID, and/or ASD. Parental sequencing can provide
further information regarding clinical significance; however, until now there have been no functional assays to aid
variant interpretation. We recruited 6 subjects from our
clinic and from the ADNP Kids parent support group,
who had features of ADNP syndrome and a missense variant (Table 2, Fig. 5). All 6 subjects had been ascertained
by clinical whole exome sequencing and received diagnostic reports listing ADNP variants as a potential cause of
their phenotype. Two individuals were fraternal twins
sharing the same missense VUS in ADNP (c.1855G>T;
p.Val619Phe). Only one variant was confirmed to be de
novo (c.201G>C; p.Gln67His). This variant affects the final
nucleotide of exon 4 and is predicted to alter splicing by
the online analysis tool, Human Splicing Finder [27]. The
c.201G>C variant was interpreted as likely pathogenic in
the exome report; all others were interpreted as VUS. All
but the c.201G>C variant were present in the gnomAD
database with minor allele frequencies < 0.01% [28].
Genome-wide methylation analysis classified five of the
six subjects as non-ADNP. The patient with the c.201G>C
variant was classified as having the ADNP-1 episignature.
Separate assessments using hierarchical clustering and
multiple dimensional scaling were also consistent with
these findings (Fig. 6).
Screening of unresolved DD/ID patients for ADNP
syndrome

Children with DD/ID frequently go undiagnosed for a
long time despite extensive diagnostic evaluation. We
asked whether epigenetic analysis could identify patients
affected with ADNP syndrome from a large cohort of
undiagnosed patients. We screened 1150 patients in two
cohorts. The first was composed of 661 subjects with developmental and intellectual disabilities with previous
genetic testing but no clear molecular diagnosis. The
second cohort was obtained from GEO (GSE89353) [29]
and included 489 subjects with both CNV and exome sequencing assessments. These patients had various forms
of syndromic and nonsyndromic DD/ID. None were suspected of having ADNP syndrome or had other confirmed genetic diagnoses. The analysis identified three
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Table 2 Classification of uncertain cases suspected of having ADNP syndrome
ADNP variant

In silico assessment d

Population allele frequency (%)e

Classification (score)

Support for prediction

Not known

N/A

N/A

ADNP-2 (0.90)

f

ADNP_26 b

c.201G>C (p.Gln67His)

Deleterious

0

ADNP-1 (0.95)

g

ADNP_01 b

ID
ADNP_18

a

c.1039A>G (p.Met347Val)

Tolerated

0.008

None (0.96)

h

b

c.2963C>T (p.Thr988Ile)

Conflicting

0.0004

None (0.97)

h, i

ADNP_19 b

ADNP_06

c.356A>G (p.Lys119Arg)

Conflicting

0.007

None (0.96)

h

b, c

c.1855G>T (p.Val619Phe)

Deleterious

0.003

None (0.95)

h, j

ADNP_28 b, c

c.1855G>T (p.Val619Phe)

Deleterious

0.003

None (0.95)

h, j

ADNP_27
a

b

This patient was a confirmed case of ADNP syndrome, but the mutation was not known at the time of the study. Reason for assessment was reporting of a
variant of unknown clinical significance in ADNP. cSubjects ADNP_27 and ADNP_28 are fraternal twins sharing a missense change with an unknown mode
of inheritance. dIn Silico assessment for the suspected variant was performed using three tools: SIFT, PolyPhen, and MutationTaster. A “tolerated” or “deleterious”
decision was assigned only if all three tools were in agreement with regard to the variant. eAllele frequency was obtained from the gnomAD database (v2.1) and
represents the combined frequencies of different subpopulations; fADNP sequencing later identified a nonsense variant in the expected ADNP-2 region:
c.2156dupA (p.Tyr719*). gVariant is absent from the general population and was classified as likely pathogenic according to the ACMG guidelines. hPopulation
minor allele frequency is too high for a dominant condition. iVariant is inherited from an unaffected mother. jNo further data is available for assessment. N/A not
applicable. ADNP transcript, NM_015339.4. Photographs of some of these subjects are provided in Additional file 1: Figure S1

subjects with ADNP-1 episignatures. Each scored > 0.75
for the ADNP-1 class (Fig. 5). Separate assessments
using hierarchical clustering and multiple dimensional
scaling revealed that all three cases have a DNA methylation profile consistent with the ADNP-1 episignature
(Fig. 6). The first subject was initially assessed for
CHARGE syndrome with clinical presentations of

A

autism spectrum disorder together with iris and retinal
colobomas, and with a non-coding VUS having been
identified in the CHARGE-associated gene, CHD7
(NM_017780.3:c.5534+16T>C). Our previous methylation analysis for CHARGE syndrome had indicated that
this patient did not have a CHARGE-associated methylation profile [17]. Following the positive screen for ADNP

B

C

Fig. 6 Separate evaluation of uncertain ADNP cases and those detected among unresolved patients. a, b Seven subjects with uncertain
diagnoses of ADNP syndrome (yellow) together with three subjects detected in the unresolved cohort (neon green) added to the clustering
analyses performed earlier in Fig. 2e and f. As expected, five of the uncertain cases are clustered with controls, one clustered with epi-ADNP-2,
and one other is clustered with epi-ADNP-2 subjects (similar to the classification by our classifier). The three unresolved cases, as expected, are
clustered with epi-ADNP-1 group. All of these cases show a DNA methylation pattern consistent with their respected predicted category. c The
updated list of causative variants detected in ADNP syndrome following the assessment of unresolved/suspected subjects is illustrated in the
ADNP protein
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syndrome, ADNP was sequenced and a pathogenic variant was detected (c.2491_2494del; p.Leu831Ilefs*82).
This was the second patient with an ADNP-1 episignature whose mutation occurred after c.2340, further supporting the hypothesis that the ADNP-2 episignature is
only caused by mutations between c.2000 and c.2340,
and defects outside this region are associated with the
ADNP-1 pattern. The second subject was obtained from
GEO (GSE89353, patient ID: Proband156) for whom the
only reported clinical feature was ASD, consistent with
the major feature of ADNP syndrome. This subject and
the third patient were not available for further assessments. These findings suggest that epigenomic profiling
can be used as a screening tool for identifying ADNP
syndrome cases among those with unresolved DD/ID.

Discussion
The past 5 years have seen a rise in the use of
genome-wide methylation arrays for identifying epigenetic
patterns associated with rare diseases. To date, 16 syndromes have been described with epigenetic signatures
[11–17, 30–32]. These profiles serve as effective adjuncts
for genomic sequencing with utility in diagnosing patients,
screening large cohorts, and clarifying the clinical relevance of variants of uncertain significance. In this study,
we identified two distinct episignatures associated with
ADNP syndrome. The classification model derived from
these data predicted true positives and negatives 100% of
the time, indicating specificity and sensitivity appropriate
for diagnostic use. Indeed, when the model was applied to
methylation data from individuals who had evaded diagnosis by traditional means, an ADNP syndrome diagnosis
was predicted in three cases. Furthermore, the results support refinement of the mutational spectrum of ADNP syndrome. (1) Variants in ADNP that result in single amino
acid substitution are unlikely to cause ADNP syndrome.
(2) Frame-shift variants in all coding exons are predicted
to cause ADNP syndrome. These findings have significant
implications for individuals and families who have received uncertain diagnoses by genetic testing, particularly
those that involve missense or synonymous changes that
could affect splicing.
In addition to classifying individual samples and variants, epigenetic profiling is useful for guiding disease classification. Recently, epigenetic profiling of Coffin-Siris and
Nicolaides-Baraitser syndromes, supported the grouping
of these disorders into a single spectrum—the BAFopathies [15]. In the current study, we provide the first description of two discrete DNA methylation signatures
arising from a single gene in a single clinical disorder.
While at the present time, a clear epigenotype/phenotype
correlation is not apparent, our data strongly suggest
unique cellular mechanisms for the two ADNP methylation episignatures. Reprocessing previously established
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episignatures with larger cohorts might reveal other conditions with discrete episignatures.
The two predominantly opposite methylation signatures
in ADNP syndrome (the ADNP-1 episignature is largely
hypomethylated; the ADNP-2 episignature is hypermethylated) lead us to suspect that each mutation sub-group has
unique cellular consequences. This genotype-epigenotype
correlation is possibly a result of differences in ADNP protein fragment length or stability causing a disruption of
DNA methylation in two unique ways. Truncating mutations scattered across the breadth of ADNP are associated
with the ADNP-1 episignature. In contrast, the ADNP-2
episignature appears to be defined by a genomic motif including variants within the c.2156–2340 cDNA positions.
This region is downstream of the nuclear localization signal (NLS) and overlaps the DNA-binding homeobox domain. When mutant ADNP protein is expressed in
HEK293T cells, truncations in this region specifically disrupt entry into the nucleus [33]. It is therefore possible
that the ADNP-2 episignature is a consequence of dominant negative protein products that enter the nucleus but
are unable to bind DNA. However, the ADNP-1 episignature results are in conflict with other observations described by Cappuyns et al., who found that ADNP protein
with exon-5 N-terminal mutations was degraded by the
proteasome [33]. Our data demonstrate that N-terminal
and C-terminal ADNP mutations affect DNA methylation
in similar ways, indicating a possibility that in both cases,
mutant protein reaches the nucleus.
One recent report associates ADNP with cognitive
abilities related to intelligence, autism, Alzheimer’s disease, and schizophrenia [6]. Correlating data from gene
expression studies with methylation patterns identified
here has the potential to advance research in many
areas. For instance, a hotspot linked to the protein SFN
is associated with both the ADNP-1 and ADNP-2 episignatures. This correlation may help to explain the
mechanism by which ADNP controls the level of the
tumor suppressor protein, p53. SFN (Stratifin, also called
14–3-3σ) expression is influenced by the methylation of
the 5′ coding sequence resulting in gene silencing in
cancer [35]. SFN regulates the stability of p53 via degradation of MDM2 [36]. In the absence of SFN, p53 is
targeted for degradation, promoting cell growth and proliferation [37]. These suggest that ADNP might influence
p53 by modifying protein stability rather than activating
gene expression as originally proposed [38].
Our clinical evaluation of the phenotyped cohort did
not reveal that patients with the two episignatures of
ADNP syndrome are separable based on clinical features
(Additional file 1: Figure S1). This is undoubtedly due to
the limited size of our phenotyped cohort (epi-ADNP-1 n
= 3; epi-ADNP-2 n = 6). A previous study assessed genotype/phenotype correlation in a very large cohort of
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subjects with ADNP syndrome [4]. The authors identified
some possible islands of correlation, but they did not
match the coordinates defined by our two episignatures.
Establishing a correlation between phenotype and epigenotype may require a larger cohort and a more uniform distribution of variants. It is also important to consider that
the strongest determinants of episignature grouping—defined in DNA isolated from blood—may not have important phenotypic relevance. This does not mean that
episignatures are unimportant, but rather that some “collateral” genomic marks are definitive biomarkers even if
they are not causative of disease. Therefore in the case of
ADNP syndrome, it may be most useful to explore the
limited DMRs with shared epigenetic patterns between
ADNP-1 and ADNP-2 episignatures.
One such area occurs in PACSIN1, which showed hypomethylation in all ADNP syndrome samples and has
a considerable overlap in cellular function with ADNP.
PACSIN1 is a neuron-specific member of the protein
kinase C and casein kinase 2 substrate family. It interacts
with dynamin and N-wasp to coordinate synaptic vesicle
endocytosis and actin polymerization [39, 40], which in
turn support neurogenesis and the maturation of dendritic spines [41]. PACSIN1 also interacts with tau proteins in neurons to reduce elongation and branching by
facilitating microtubule instability [42]. Conversely,
ADNP is required for neurite outgrowth in cell culture
and the NAP peptide promotes outgrowth and branching [43]. Heterozygous ADNP knockout mice develop
tauopathies, possibly due to the fact that NAP interacts
with the neuronal microtubule network [44]. Given the
consistently hypomethylated region of PACSIN1 detected in the ADNP cohort and the functional overlap of
these proteins, we believe that the relationship between
PACSIN1 and ADNP warrants further study.

Conclusions
This study describes the first evidence of a Mendelian
condition with two distinct peripheral blood episignatures caused by mutations in a single gene. These results
suggest that two unique functional properties contribute
to ADNP syndrome. These highly sensitive and specific
DNA methylation episignatures in peripheral blood enable the diagnosis, screening, and classification of
ADNP-suspected patients with genetic VUSs, and provide novel avenues for implementation of this technology in clinical diagnostic laboratories.
Methods
Patients and cohorts

Peripheral blood genomic DNA samples from patients
with ADNP syndrome were obtained from the following
sources: The Greenwood Genetic Center (Greenwood,
SC, USA), collaborations established through the
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GeneMatcher exchange [45], and families in partnership
with the ADNP Kids parent support group (https://
www.adnpkids.com).
The first set of controls that were used for mapping of
the episignatures, feature selection, and model training
were collected from the Greenwood Genetic Center and
the reference cohort in LHSC laboratory. A larger set of
controls that were later used to measure the specificity
of the classification model developed later in the study
were compiled from five large databases of general
population samples with various age and racial backgrounds (GSE42861, GSE85210, GSE87571, GSE87648,
and GSE99863) [20–23].
Samples, from patients with congenital syndromes
other than ADNP syndrome and those caused by mutations in other regulators of the epigenomic machinery
that were only used for measuring the specificity of the
classification model, comprised data described in our
previous studies [11, 14–17, 46, 47] and included a large
group of patients with autosomal dominant cerebellar
ataxia with deafness and narcolepsy, ATRX syndrome,
Claes-Jensen syndrome, CHARGE syndrome, CHOPS
syndrome, Cornelia de Lange syndrome, Down syndrome, Fragile X syndrome, Floating-Harbor syndrome,
Genitopatellar syndrome, Juberg-Marsidi syndrome, Kabuki syndrome, Angelman syndrome, Prader-Willi syndrome, Beckwith-Wiedemann syndrome, Coffin-Lowry
syndrome, Rett syndrome, Saethre-Chotzen syndrome,
Sotos syndrome, autism spectrum disorders, BAFopathies, and RASopathies. Added to this cohort were samples from patients with Silver-Russell syndrome, Weaver
syndrome, Williams syndrome, and chr7q11.23 duplication syndrome, which were downloaded from gene expression omnibus (GEO–GSE104451, GSE55491,
GSE74432, and GSE66552) [15, 48–50]. We supplemented the cohort of subjects with CHARGE syndrome,
Sotos syndrome, Kabuki syndrome, and Down syndrome
with publically available DNA methylation data from
GEO (GSE74432, GSE116300, GSE97362, GSE52588)
[13, 30, 51]. While all of these syndromes represent clinical features overlapping with ADNP syndrome, i.e., intellectual disability and facial dysmorphism, others are
associated with specific DNA methylation patterns
across the genome. We used this cohort to confirm that
the DNA methylation episignature of ADNP syndrome
does not overlap with other constitutional disorders.
Any subject used herein to represent a condition had a
confirmed clinical diagnosis of the aforementioned syndrome and was screened for mutations in the related
genes. The mutation report from every patient was
reviewed according to the American College of Medical
Genetics and Genomics (ACMG) guidelines for interpretation of genomic sequence variants [52], and only
individuals confirmed to carry a pathogenic or likely
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pathogenic mutation together with the clinical diagnosis
were used to represent a syndrome.
Samples with uncertain diagnoses as well as unsolved
cases, which were used to assess the diagnostic potentials of the ADNP DNA methylation episignatures, were
collected from all of the sources above over a period of
4 years. These samples were supplemented with publically available DNA methylation files from GEO for a
cohort of unsolved subjects with neurodevelopmental
disorders/congenital anomalies (GSE89353) [29].
Methylation array and quality control

Peripheral whole blood DNA was extracted using standard techniques. Following bisulfite conversion, DNA
methylation analysis of the samples was performed using
the Illumina Infinium methylation 450 k or EPIC bead
chip arrays (San Diego, CA), according to the manufacturer’s protocol. The resulting methylated and unmethylated signal intensity data were imported into R 3.5.1 for
analysis. Normalization was performed using the Illumina normalization method with background correction
using the minfi package [53]. Probes with detection p
value > 0.01, those located on chromosomes X and Y,
those known to contain SNPs at the CpG interrogation
or single nucleotide extension, and probes known to
cross-react with chromosomal locations other than their
target regions were removed. Arrays with more than 5%
failure probe rate were excluded from the analysis. Sex
of the subjects was predicted using the median signal intensities of the probes on the X and Y chromosomes and
those samples discordant between the labeled and predicted sex were not used for analysis. All of the samples
were examined for genome-wide methylation density,
and those deviating from a bimodal distribution were excluded. Factor analysis using a principal component analysis (PCA) was performed to examine the batch effect
and identify the outliers.
Selection of matched controls for methylation profiling

Matched controls were randomly selected for methylation profiling or feature selection. All of the ADNP samples were assayed using the EPIC array. Therefore, only
controls assayed using the same platform were used for
the analysis. Matching was done by age and sex using
the MatchIt package. The control sample size was increased until both the matching quality and sample size
were optimized and consistent across all analyses. This
led to the determination of a control sample size four
times larger than that of the cases in every analysis. Increasing the sample size beyond this value compromised
the matching quality. After every matching trial, a PCA
was performed to detect outliers and examine the data
structures. Outlier samples and those with aberrant data
structures were removed before a second matching trial
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was conducted. The iteration was repeated until no outlier sample was detected in the first two components of
the PCA.
DNA methylation profiling of ADNP syndrome

The analysis was performed according to our previously
published protocol [15, 17, 54, 55]. The methylation
level for each probe was measured as a beta value, calculated from the ratio of the methylated signals vs. the
total sum of unmethylated and methylated signals, ranging between zero (no methylation) and one (full methylation). This value was used for biological interpretation
and visualization. For linear regression modeling, beta
values were logit transformed to M-values using the following equation: log2(beta/(1 − beta)). A linear regression modeling using the limma package [56] was used to
identify the differentially methylated probes. The analysis
was adjusted for blood cell type compositions, estimated
using the algorithm developed by Houseman et al. [57].
The estimated blood cell proportions were added to the
model matrix of the linear models as confounding variables. The generated p values were moderated using the
eBayes function in the limma package and were corrected for multiple testing using the Benjamini and
Hochberg method. Probes with a corrected p value <
0.01 and a methylation difference greater than 10% were
considered significant. The effect size cutoff of 10% was
chosen to avoid reporting of probes with low effect size
and those influenced by technical or random variations
as conducted in our previous studies [15, 17].
Clustering and dimension reduction

Following every analysis, the selected probes were examined using a hierarchical clustering and a multiple dimensional scaling to examine the structure of the
identified episignature. Hierarchical clustering was performed using Ward’s method on Euclidean distance by
the gplots package. Multiple dimensional scaling was
performed by scaling of the pair-wise Euclidean distances between the samples.
Identification of the differentially methylated regions

To identify genomic regions harboring methylation
changes (differentially methylated regions—DMRs), the
DMRcate algorithm was used [18]. First, the p values
were calculated for every probe using multivariable
limma regression modeling. Next, these values were kernel smoothed to identify regions with a minimum of
three probes no more than 1 kb apart and an average regional methylation difference > 10%. We selected regions
with a Stouffer transformed false-discovery rate (FDR) <
0.01 across the identified DMRs. The analysis was performed on the same sets of cases and controls used for
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methylation profiling and was adjusted for blood cell
type compositions.
Gene-set and pathway enrichment analysis and
identification of differential methylation interaction
hotspots

Gene-set enrichment analysis was performed using the missMethyl package [58]. We identified Gene Ontology (GO)
terms overrepresented in the genes associated with differentially methylated probes in ADNP syndrome, taking into
account the number of CpG sites per gene. All CpG sites
tested in the analysis were included as the background for
the enrichment analysis. The enriched GO terms with an
FDR < 0.01 were considered significant. Pathway enrichment analysis was conducted using a hypergeometric
model implemented in the ReactomePA package [59].
Genes annotated to all of the probes passing quality controls in the EPIC array were used as the background.
Enriched pathways with FDR < 0.01 were reported.
We used the EpiMod algorithm [34] to search for the
interactome hotspots of differential promoter methylation.
In this algorithm, protein expression changes are inferred
according to a model of inverse association between the
promoter methylation and gene expression. Among the
differentially expressed genes in an interactive network, a
hotspot (epigenetic module (EpiMods)) is a sub-network
with an exceptionally large average edge-weight density
(combined methylation statistics of the neighboring genes)
as compared to the rest of the network [34]. To assign a
statistical significance to the identified hotspots, 1000
Monte Carlo randomization of the molecular profiles was
conducted as suggested by the algorithm. Interactive network hotspots composed of at least ten genes and FDR <
0.01 were reported.
Construction of a classification model for ADNP syndrome

To construct a classification model for ADNP syndrome,
subjects were divided into training (75%) and testing (25%)
cohorts, ensuring that the two ADNP subtypes later identified were equally represented in both of the training and
testing cohorts. For each of the subtypes in the training cohort, a matched group of controls with a sample size of
four times larger was selected. Given the majority of the
samples to be tested later were assayed using 450k array,
we limited the analysis to probes shared by both array
types. In order to avoid the use of probes with low effect
size and those susceptible to technical variation, we further
restricted the probes showing a minimum of 10% methylation difference between each ADNP subtype and controls.
The intersection of the two lists was used for feature selection. Using the filterVarImp function in the Caret package
[60], for each probe we measured pairwise area under the
receiver operating characteristic curve (AUC) between each
of the two subtypes and controls. Probes that obtained the
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maximum AUC in all three pairwise iterations were selected (all three variable importance measures = 1). This
final probe list was used to train a multi-class support vector machine (SVM) with linear kernel on the training cohort. Training was done using the e1071 R package. To
determine the best hyperparameter used in linear SVM
(cost—C), and to measure the accuracy of the model,
10-fold cross-validation was performed during the training.
In this process, the training set was randomly divided into
ten folds. Nine-fold was used for training the model and
one fold for testing. After 10-fold repeating of this iteration,
the mean accuracy was calculated, and the hyperparameters
with the most optimal performance were selected. For
every subject, the model was set to generate three scores
ranging 0–1, representing the confidence in predicting
whether the subject has a DNA methylation profile similar
to ADNP-1, ADNP-2, or controls. Conversion of SVM decision values to these scores was done according to the
Platt’s scaling method [61]. The class obtaining the greatest
score determined the predicted phenotype. The final model
was applied to both training and testing datasets to ensure
the success of the training.
Validation of the classification model

We ensured that the model is not sensitive to the batch
structure of the methylation experiment by applying it
to all of the samples assayed on the same batch as the
patients used for training. To confirm that the classifier
is not sensitive to the blood cell type compositions, we
downloaded methylation data from isolated cell populations of healthy individuals from GEO (GSE35069) [19],
supplied them to the classification model for prediction,
and examined the degree to which the scores were varied across different blood cell types. Next, the model
was applied to the testing cohort (25% subset of the patients not used for feature selection or training) to evaluate the predictive ability of the model on affected
subjects. To determine the specificity of the model, we
supplied a large number of DNA methylation arrays
from healthy subjects to the model. To understand
whether this model was sensitive to other medical conditions presenting with developmental delay and intellectual disabilities, we tested a large number of subjects
with a confirmed clinical and molecular diagnosis of
such syndromes by the model.
Screening of undiagnosed and uncertain cases

The finally confirmed model was used to classify subjects suspected of having ADNP syndrome including
those with no sequence variant or with variants of unknown significance (VUS). In addition, we used the
model to screen a large group of individuals with various
forms of neurodevelopmental presentations but no
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established diagnosis despite routine clinical and molecular assessments. The subjects that were predicted to
have any of the ADNP subtypes were evaluated based on
both the clinical and molecular information. Wherever a
sequence variant was found, in silico assessment was
performed to provide support for the predictions using
SIFT, PolyPhen, and MutationTaster [62–64].
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